Francisco Partners to Sell Medication Management Company Aesynt to Omnicell

Francisco Partners, a leading technology-focused private equity firm, today announced it has signed a definitive agreement to sell Aesynt to Omnicell, Inc. (NASDAQ: OMCL) (omnicell.com) for $275 million. Francisco Partners acquired Aesynt in October 2013.

“It has been a true pleasure to partner with the Aesynt management team to transform the business,” said Chris Adams, partner at Francisco Partners and chairman of the Aesynt board of directors. “Through significant investment in new products – particularly new enterprise medication management software – the team significantly revitalized the organization and returned it to rapid growth.”

Aesynt enables health systems to reduce cost and improve patient safety through the integration, automation, and management of medication preparation and delivery system-wide with the industry’s most comprehensive medication management portfolio.

“Francisco Partners provided valuable strategic support, capital, and resources that allowed us to execute on a strategic vision that fueled new growth,” said Kraig McEwen, Aesynt CEO. “Today, healthcare organizations embrace Aesynt’s robust medication management tools, which will complement Omnicell’s product portfolio and international footprint.”

“Aesynt brings distinct capacities in dispensing systems, central pharmacy robotics, IV robotics and analytics,” said Randall Lipps, CEO of Omnicell. “We expect that as a combined entity we can accelerate innovation in the marketplace by leveraging the combined strengths of the Aesynt and Omnicell teams. Choice, innovation and value make this a great acquisition for Omnicell and our customers.”

Omnicell’s financial advisor in this transaction was Greenhill & Co., LLC and Sidley Austin LLP, Cooley LLP and Jones Day served as legal counsel. Francisco Partners was advised by Robert W. Baird & Co. and Kirkland & Ellis LLP.

About Francisco Partners
Francisco Partners is a leading global private equity firm, which specializes in investments in technology and technology-enabled services businesses. Since its launch over 15 years ago, Francisco Partners has raised approximately $10 billion in capital and invested in more than 150 technology companies, making it one of the most active and longstanding investors in the technology industry. The firm invests in transaction values ranging from $50 million to over $2 billion, where the firm's deep sectoral knowledge and operational expertise can help companies realize their full potential. Francisco Partners has invested in 15 healthcare technology companies to-date.

ABOUT AESYNT
Aesynt designs and assembles robotics and automation products to help large hospital pharmacies and health systems manage, store, and distribute pharmaceutical drugs. Aesynt offers automation solutions at every stage of medication delivery – including Central Pharmacy, Point of Care, Packaging and Preparation and Ordering and Receiving. Through the use of robotics, bar-code scanning automation and web-based technologies, Aesynt’s portfolio of pharmacy automation solutions enhance medication ordering, dispensing, administration, charge capture and inventory management processes. Aesynt’s solutions are used by over 1,200 hospital customers and many of the largest medical organizations in the world.